Dihydropelitinib
Dihydropelitinib (DHP) is a ILK ligand with a Kd value of 252 nM. Dihydropelitinib acts as a cytoskeleton modulator that induces actin (Actin) cytoskeleton rearrangement. Dihydropelitinib exhibits anticancer activity against liver cancer and lung adenocarcinoma. Dihydropelitinib can be used in studies related to liver cancer and lung adenocarcinoma.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 分子式: C24H25ClFN5O2
- 分子量:469.94
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
製品説明
体外実験
Dihydropelitinib (0.019-2.500 μM) binds specifically to the ILK:α-parvin complex, with an equilibrium dissociation constant (Kd) of 252 nM[1].
Dihydropelitinib (serial dilution; 2 h treatment) binds to full-length ILK in digitonin (HY-N4000)-permeabilized HEK293T cells, with an IC50 of 980 nM as determined by NanoBRET target binding assay[1].
Dihydropelitinib (0.22-2.50 μM; 48 h) induces concentration-dependent rearrangement of the actin cytoskeleton in hepatocellular carcinoma Huh-7 cells after 48 h of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
分子量 469.94
-
分子式 C24H25ClFN5O2
-
SMILES
FC(C=CC(NC1=C(C=NC2=CC(OCC)=C(NC(CCCN(C)C)=O)C=C12)C#N)=C3)=C3Cl
-
別名
DHP
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)